/
PMCB
$0.73-$0.04 (-5.03%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$8.3M
11M shares
52-week range
$0.63 – $1.51
11% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
46.13%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-2.30
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $2.0M | $460.1K | $301.2K | $916.2K | $690.9K | $468.5K | $407.4K | $438.4K |
| Operating income | −$7.0M | −$4.1M | −$3.8M | −$3.6M | −$4.4M | −$6.5M | −$6.5M | −$4.4M |
| EBITDA | $0 | $0 | −$40 | −$3.5M | −$4.2M | −$4.3M | $6.9M | $30.7M |
| Net income | −$6.8M | −$4.1M | −$3.8M | −$3.6M | −$4.2M | −$4.3M | $333.8K | $30.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -10.57 | -5.55 | -4.23 | -2.46 | -0.79 | -0.83 | -1.80 | 3.19 |
Annual figures · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.49
Price
$0.73
Implied upside
+241%
Peer comparison
PharmaCyte Biotech, Inc. Common Stock
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
pharmacyte.com- Employees
- 2
- IPO / List date
- Sep 11, 2003
- HQ
- LAS VEGAS, NV
Held by traders on TradeandTell
No one on the platform currently holds PMCB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 56,500 | $37.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2021-07-12 | 1-for-1500reverse |
| 2003-12-08 | 3-for-1 |
Recent trades on TradeandTell
No one on the platform has traded PMCB yet.
